Did you know?

SALT LAKE CITY, April 11, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S ...Recursion Pharmaceuticals Stock Down 2.6 %. Shares of NASDAQ RXRX opened at $9.63 on Monday. The business has a 50-day simple moving average of $8.96 and a two-hundred day simple moving average of ...Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ...AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed …

The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by Needham on January 17, 2024.The analyst firm set a price target for $15.00 expecting RXRX to rise to within ... 1 day ago · The Nasdaq Composite rose like a phoenix from the ashes in 2023, but history suggests there's more growth to come. Generative AI kick-started the market last year, but it's still early innings for ... Recursion Pharmaceuticals (NASDAQ:RXRX) has built one of the world’s most advanced AI-powered platforms to help decode human biology. RXRX gathers data and experiments on millions of biological ...Data is delayed at least 15 minutes. Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the …

Market Activity. Funds + ETFs. News + Insights. P/E & PEG Ratios. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm ... Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Nasdaq. 15,415.02 +104.05 (+0.68%) ... Investors in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have tasted that bitter downside in the last year, as the share price dropped 20%. That's ... ….

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Nasdaq rxrx. Possible cause: Not clear nasdaq rxrx.

Recursion Pharmaceuticals ( NASDAQ: RXRX) - the subject of this analysis - IPOd in April 2021, issuing 27.88m shares at a price of $18 per share, and raising >$500m - making it the sixth largest ...Recursion Pharmaceuticals Insider Sold Shares Worth $117,180, According to a Recent SEC Filing. Nov. 17. MT. Recursion Pharmaceuticals Insider Sold Shares Worth $340,929, According to a Recent SEC Filing. Nov. 17. MT. JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating.RXRX Recursion Pharmaceuticals Inc Form 144 ... Recursion Pharmaceuticals (NASDAQ:RXRX) Historical Stock Chart From Dec 2023 to Jan 2024 Recursion Pharmaceuticals (NASDAQ: ...

Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. The idea of Recursion Pharmaceuticals (RXRX-4.65%) is to throw petabytes of data on biological targets, chemical interactions, and bioactive molecules at a machine learning platform to identify ...

todaypercent27s cryptoquip solution Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.2023-09-11 09:35:31 ET. Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug development, it could soon mark itself as the leading competitor in a space that will probably prove to be quite lucrative. 5 star nails and spaflym sks ayrany Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...Ignatiev. At a Glance. Recursion Pharmaceuticals (NASDAQ:RXRX) is carving out a vanguard role in TechBio by synergizing wet-lab biology with advanced computational tools.The firm's Q2 earnings ... jose joaquin de herrera Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... todaypercent27s cryptoquip solutionteamvorstellung jan w.auriza hero Recursion Pharmaceuticals (NASDAQ: RXRX) exploded in July on the strength of hot news—a $50 million direct investment from Nvidia (NASDAQ: NVDA). Since that month’s high, shares are back in ... cuanto paga el mega million por 1 numero Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... blogkenosha news obitsbehavioral science masterrisoluzione del contratto di fornitura In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.38) by $0.05 with a reported earnings per share (EPS) of ($0.43). Learn more on analysts' earnings estimate vs. RXRX's actual earnings.